Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability, pharmacokinetics, and efficacy of kukoamine B in patients with sepsis: A randomized phase IIa trial.
Hu XY, Zhang W, Wang D, Sun Y, Hu Z, Zang B, Feng Y, Wang H, Zhou J, Zhao Q, Liu H, Wang T, Jiang W, Wang CY, Jin C, Dong K, Chen S, Yao X, Hu P, Du B; China Critical Care Clinical Trials Group (CCCCTG). Hu XY, et al. Among authors: dong k. J Crit Care. 2023 Aug;76:154294. doi: 10.1016/j.jcrc.2023.154294. Epub 2023 Apr 26. J Crit Care. 2023. PMID: 37116228 Clinical Trial.
Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies.
Jiang J, Zou X, Liu Y, Liu X, Dong K, Yao X, Feng Z, Chen X, Sheng L, Li Y. Jiang J, et al. Among authors: dong k. Front Pharmacol. 2021 Jun 21;12:677120. doi: 10.3389/fphar.2021.677120. eCollection 2021. Front Pharmacol. 2021. PMID: 34234673 Free PMC article.
Erratum: Author correction to "YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer" [Acta Pharmaceutica Sinica B 12 (2022) 2845-2858].
Lai F, Ji M, Huang L, Wang Y, Xue N, Du T, Dong K, Yao X, Jin J, Feng Z, Chen X. Lai F, et al. Among authors: dong k. Acta Pharm Sin B. 2023 Jul;13(7):3178-3179. doi: 10.1016/j.apsb.2023.05.003. Epub 2023 May 9. Acta Pharm Sin B. 2023. PMID: 37521865 Free PMC article.
Pharmacologically significant constituents collectively responsible for anti-sepsis action of XueBiJing, a Chinese herb-based intravenous formulation.
Cheng C, Ren C, Li MZ, Liu YH, Yao RQ, Yu Y, Yu X, Wang JL, Wang LX, Leng YC, Zhang H, Du FF, Dong N, Wang FQ, Wu Y, Xu F, Zhu XM, Zhang GP, Dong K, Liu S, Yao XQ, Li C, Yao YM. Cheng C, et al. Among authors: dong n, dong k. Acta Pharmacol Sin. 2024 May;45(5):1077-1092. doi: 10.1038/s41401-023-01224-1. Epub 2024 Jan 24. Acta Pharmacol Sin. 2024. PMID: 38267547
Influence of F-containing Materials on Perovskite Solar Cells.
Dong K, Zhu L, Yang G, Zheng L, Wang Y, Zhang B, Zhou J, Bian J, Zhang F, Yu S, Liu S, Wang M, Xiao JD, Guo X, Jiang X. Dong K, et al. ChemSusChem. 2024 May 21:e202400038. doi: 10.1002/cssc.202400038. Online ahead of print. ChemSusChem. 2024. PMID: 38771426
Site-Specifically Modified Peptide Inhibitors of Protein Tyrosine Phosphatase 1B and T-Cell Protein Tyrosine Phosphatase with Enhanced Stability and Improved In Vivo Long-Acting Activity.
Zhang C, Yang X, Wu L, Liu F, Dong K, Guo C, Gong L, Dong G, Shi Y, Gu Z, Liu X, Liu S, Wu J, Su F. Zhang C, et al. Among authors: dong k. ACS Pharmacol Transl Sci. 2024 Apr 24;7(5):1426-1437. doi: 10.1021/acsptsci.4c00054. eCollection 2024 May 10. ACS Pharmacol Transl Sci. 2024. PMID: 38751623
2,133 results